LiverLearning®: 2021 Webinar: FY21 Peer Reviewed Cancer Research Program Funding Opportunities in Liver Cancer

The Peer Reviewed Cancer Research Program webinar will present funding opportunities for liver cancer through the Department of Defense. This webinar will cover topics including how to apply, what opportunities are available, as well as hints and tips on how to succeed in applying to the Department of Defense Congressionally Directed Medical Research Programs.Donna M. Kimbark Donna M. Kimbark, PhD currently serves as the Program Manager at the Congressionally Directed Medical Research Programs, U.S. Army Medical Research and Development Command. In 1996, Dr.

Differences Between Infectious Disease Events in First Liver Transplant Versus Retransplantation in the Swiss Transplant Cohort Study

Katharina Kusejko, Dionysios Neofytos, Hans H. Hirsch, Pascal Meylan, Katia Boggian, Cedric Hirzel, Christian Garzoni, Roger D. Kouyos, Nicolas J. Mueller, Peter W. Schreiber, the Swiss Transplant Cohort Study – 9 April 2021 – Retransplantation after graft failure is increasingly performed, and inferior graft survival, patient survival, and quality of life has been reported. The role of infectious disease (ID) events in this less favorable outcome is unknown. We analyzed ID events after first liver transplantation (FLTpx) and retransplantation (reLTpx) in the Swiss Transplant Cohort Study.

Impact of Aging on Liver Cells and Liver Disease: Focus on the Biliary and Vascular Compartments

Leonardo Baiocchi, Shannon Glaser, Heather Francis, Lindsey Kennedy, Eric Felli, Gianfranco Alpini, Jordi Gracia‐Sancho – 9 April 2021 – The aging process is represented by the time‐dependent decay in physiologic functions of living beings. Major interest has been focused in recent years on the determinants of this progressive condition due to its correlative relationship with the onset of diseases. Several hallmark features have been observed in aging, such as genetic alterations, mitochondrial impairment, and telomere shortening.

Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity

Vincent Jacques, Sébastien Bolze, Sophie Hallakou‐Bozec, Anthony W. Czarnik, Ajit S. Divakaruni, Pascale Fouqueray, Anne N. Murphy, Lex H.T. Van der Ploeg, Sheila DeWitt – 9 April 2021 – The antidiabetic drug pioglitazone is, to date, the most efficacious oral drug recommended off‐label for the treatment of nondiabetic or diabetic patients with biopsy‐proven nonalcoholic steatohepatitis (NASH). However, weight gain and edema side effects have limited its use for NASH.

Feasibility and Effectiveness of Norepinephrine Outside the Intensive Care Setting for Treatment of Hepatorenal Syndrome

Allison Kwong, W. Ray Kim, Paul Y. Kwo, Uerica Wang, Xingxing Cheng – 9 April 2021 – Vasoconstrictors are the treatment of choice for hepatorenal syndrome (HRS). We evaluate the real‐life effectiveness of a sequential vasoconstrictor regimen of midodrine–octreotide followed by norepinephrine in a nonintensive care unit (non‐ICU) setting in the United States, where terlipressin is not available. The diagnosis of HRS and definitions of response to therapy were based on 2015 guidelines from the International Club of Ascites.

Atherogenic Dyslipidemia After Liver Transplantation: Mechanisms and Clinical Implications

Taseen Syed, Mohammad S. Siddiqui – 9 April 2021 – Cardiovascular disease (CVD), particularly atherosclerosis‐associated CVD, is a major cause of long‐term mortality after liver transplantation (LT). The liver is central in lipid homeostasis, and changes associated with insulin resistance, weight gain, adipose tissue inflammation, and development of nonalcoholic fatty liver disease (NAFLD) after LT promote atherogenesis.

Subscribe to